Understanding Kaposiform Lymphangiomatosis
At a Glance
Kaposiform lymphangiomatosis (KLA) is a rare lymphatic disorder that can affect several body systems, especially the chest, and lower platelets and a clotting protein. NRAS testing may help guide targeted treatment with sirolimus or MEK inhibitors such as trametinib.
Receiving a diagnosis of Kaposiform lymphangiomatosis (KLA) often feels like entering a world of medical terms you have never heard before. Because KLA is extremely rare, you may have already faced a long journey of “near-miss” diagnoses, such as pneumonia or more common vascular marks, before reaching this point [1][2].
While the name sounds complex, it describes a specific way the body’s lymphatic system—the network of vessels that move fluid and support the immune system—develops and behaves [3]. In KLA, these vessels are not just malformed; they are accompanied by clusters of specialized “spindle-shaped” cells that cause the disease to act more aggressively than other lymphatic conditions [3][4].
Understanding the Rarity and Onset
KLA is a rare condition, and because it is so uncommon, there is no single “typical” experience. Most often, symptoms begin in childhood; in one specific imaging study, the median age when symptoms first appeared was roughly 6.5 years old [5]. However, this is just a single study’s finding, and the range is wide: some children are diagnosed as infants, while others may not show signs until their late 20s [5][6].
Because it is so rare, many doctors may never see a case in their entire career. This often means that families must travel to specialized vascular anomaly centers where expertise is concentrated [2][7]. Finding out that your child has a condition that “no one has heard of” can be isolating, but it is important to know that a dedicated international community of researchers and families is actively working to understand and treat KLA [7].
A Multi-System Condition
KLA is described as a multisystem disease because it often affects several parts of the body at once, particularly within the thoracic cavity (the chest area) [5]. It is not a traditional cancer that starts in one spot and metastasizes; rather, the lymphatic vessels are affected in multiple areas simultaneously [8].
Common areas of involvement include:
- The Mediastinum: This is the space in the middle of the chest between the lungs. In one reported 20-patient study, 100% of patients had involvement in this area [5].
- Lungs and Pleura: The disease often affects the lung tissue itself or the pleura (the thin lining around the lungs) [5]. This can lead to pleural effusions, which is a buildup of fluid that can make breathing difficult [5].
- The Pericardium: This is the sac surrounding the heart. Fluid can sometimes build up here as well, which requires close monitoring by your medical team [5].
- Bone and Other Organs: While the chest is the most common site, KLA can also involve the bones, the spleen, or the area behind the abdominal organs (retroperitoneum) [5].
The Role of Blood and Clotting
One of the most important ways KLA differs from other lymphatic anomalies is how it affects the blood. KLA can cause thrombocytopenia (low platelet counts) and low levels of fibrinogen (a protein that helps blood clot) [9][10]. This happens because the abnormal lymphatic vessels can “trap” or consume these clotting factors, a process sometimes called consumptive coagulopathy [9]. This can lead to an increased risk of bleeding, which is why regular blood tests are a standard part of KLA care [10][3].
New Horizons in Research and Treatment
For a long time, the cause of KLA was a mystery. However, recent breakthroughs have identified a “genetic driver” in the majority of cases—a specific mutation in a gene called NRAS [11][12]. This is a somatic mutation, meaning it is a change that occurred in the affected tissue during development; it is not inherited through the germline and generally not passed on to others [11]. Keep in mind a negative test does not completely rule out KLA.
This discovery has changed the landscape of treatment. Instead of relying only on general therapies, doctors can now use targeted therapies that specifically block the signals sent by this mutation:
- Sirolimus: A medication that has helped many patients stabilize their disease and improve their symptoms [13].
- MEK Inhibitors (such as Trametinib): These are newer treatments that target the pathway specifically affected by the NRAS mutation. Early reports have shown they can be very effective at reducing fluid buildup and improving blood counts in some patients [14][15].
While KLA remains a serious and aggressive condition, these scientific advances mean that we are moving away from uncertainty and toward treatments designed for the specific biology of the disease [16][17].
Common questions in this guide
What is Kaposiform lymphangiomatosis?
Which parts of the body can KLA affect?
How can KLA affect blood tests and bleeding risk?
Does an NRAS mutation mean that KLA is inherited?
What treatments are used for Kaposiform lymphangiomatosis?
Why might someone with KLA need a vascular anomalies center?
Get notified when new evidence is published on Kaposiform lymphangiomatosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Perioperative Considerations for a Patient with Juvenile Idiopathic Scoliosis and Kaposiform Lymphangiomatosis Undergoing Spinal Fusion: A Case Report.
Avendano JP, Rauf R, Vickers B, et al.
Journal of orthopaedic case reports 2025; (15(5)):103-108 doi:10.13107/jocr.2025.v15.i05.5572.
PMID: 40351635 - 2
Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment.
McDaniel CG, Adams DM, Steele KE, et al.
Pediatric blood & cancer 2023; (70(4)):e30219 doi:10.1002/pbc.30219.
PMID: 36683202 - 3
Kaposiform Lymphangiomatosis: Pathologic Aspects in 43 Patients.
Perez-Atayde AR, Debelenko L, Al-Ibraheemi A, et al.
The American journal of surgical pathology 2022; (46(7)):963-976 doi:10.1097/PAS.0000000000001898.
PMID: 35385405 - 4
Potential biomarkers of kaposiform lymphangiomatosis.
Ozeki M, Nozawa A, Kawamoto N, et al.
Pediatric blood & cancer 2019; (66(9)):e27878 doi:10.1002/pbc.27878.
PMID: 31207041 - 5
Imaging features of kaposiform lymphangiomatosis.
Goyal P, Alomari AI, Kozakewich HP, et al.
Pediatric radiology 2016; (46(9)):1282-90 doi:10.1007/s00247-016-3611-1.
PMID: 27053281 - 6
Recurrent haemoptysis: a rare diagnosis of kaposiform lymphangiomatosis and review of literature.
Fedidat R, Elia A, Hershko A, Fridlender Z
BMJ case reports 2022; (15(9)) doi:10.1136/bcr-2022-250825.
PMID: 36171013 - 7
Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus.
Iacobas I, Adams DM, Pimpalwar S, et al.
Pediatric blood & cancer 2020; (67(1)):e28036 doi:10.1002/pbc.28036.
PMID: 31617676 - 8
Complex Lymphatic Anomalies: A Comprehensive Review of Imaging Features and Diagnostic Considerations.
Pratt M, Dillenbeck J, Pimpalwar S, et al.
Seminars in roentgenology 2026; (62()):150967 doi:10.1016/j.ro.2025.150967.
PMID: 41349185 - 9
Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.
Ji Y, Chen S, Peng S, et al.
Orphanet journal of rare diseases 2019; (14(1)):165 doi:10.1186/s13023-019-1147-9.
PMID: 31277673 - 10
[Clinical characteristics of Kaposiform lymphangiomatosis: a report of 8 cases].
Qiu T, Yang KY, Peng SH, et al.
Zhonghua wai ke za zhi [Chinese journal of surgery] 2019; (57(12)):921-926 doi:10.3760/cma.j.issn.0529-5815.2019.12.010.
PMID: 31826597 - 11
A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.
Barclay SF, Inman KW, Luks VL, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(7)):1517-1524 doi:10.1038/s41436-018-0390-0.
PMID: 30542204 - 12
Lyve1-Driven NrasQ61R Causes Edema, Enlarged Lymphatic Vessels, and Hepatic Vascular Defects in Embryonic Mice.
McDaniel CG, Fox D, Pastura P, et al.
Pediatric blood & cancer 2025; (72(3)):e31492 doi:10.1002/pbc.31492.
PMID: 39723841 - 13
Sirolimus in the treatment of kaposiform lymphangiomatosis.
Zhou J, Yang K, Chen S, Ji Y
Orphanet journal of rare diseases 2021; (16(1)):260 doi:10.1186/s13023-021-01893-3.
PMID: 34103076 - 14
Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.
Chowers G, Abebe-Campino G, Golan H, et al.
Pediatric research 2023; (94(6)):1911-1915 doi:10.1038/s41390-022-01986-0.
PMID: 35246606 - 15
Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.
Brown G, McNab S, Keogh S, et al.
Case reports in pediatrics 2026; (2026()):7037459 doi:10.1155/crpe/7037459.
PMID: 42639465 - 16
MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.
Alharbi S, Wagner A, Merkle S, et al.
Pediatric blood & cancer 2026; (73(3)):e70002 doi:10.1002/1545-5017.70002.
PMID: 41496696 - 17
Efficacy and Safety of Trametinib Therapy for Complex Lymphatic Malformations.
Xu Y, Zhou J, Lan Y, Ji Y
Pediatric blood & cancer 2026; (73(1)):e32119 doi:10.1002/pbc.32119.
PMID: 41116710
This overview of Kaposiform lymphangiomatosis is for educational purposes and does not replace medical advice. A vascular anomalies team and other specialists should interpret your blood tests, imaging, genetic results, and treatment options.